2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Biliary Tract Neoplasms
5
Cholangiocarcinoma
4
Lymphoma, B-Cell
2
Recurrence
1
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
1
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Klatskin Tumor
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
fludarabine phosphate
29
Etoposide
26
pegaspargase
24
Peripheral Blood Stem Cell Transplantation
23
Cyclophosphamide
23
Whole-Body Irradiation
21
Mycophenolic Acid
21
Gemcitabine
19
Busulfan
19
Methotrexate
16
Dexamethasone
16
Tacrolimus
15
Cyclosporine
14
Antilymphocyte Serum
13
Radiotherapy
12
Oxaliplatin
10
Rituximab
9
Melphalan
8
Asparaginase
8
Doxorubicin
7
Bortezomib
7
spartalizumab
6
Vorinostat
6
Lenalidomide
6
Flow Cytometry
6
tislelizumab
5
Vincristine
5
Therapeutics
5
Methylprednisolone
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Extranodal NK-T-Cell
×
gemcitabine-oxaliplatin regimen
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled